ARG-007’s unique mechanism of action and proven safety profile position it as a strong contender in the acute ischaemic stroke treatment landscape.
Argenica Therapeutics is advancing its novel neuroprotective drug ARG-007 through a promising Phase 2 trial, with no adverse events reported and potential applications in multiple neurological conditions.
Tryptamine Therapeutics has successfully completed its Phase 1b trial for TRP-8803, marking a significant step forward in the development of its innovative psilocin-based therapy.
Pivotal trials which could position an Australian therapeutic as a leading candidate in the fight against stroke continue on pace.
Immuron heads toward a third set of Phase 2 clinical studies after pre-clinical success against a deadly infection.
OTC Markets is expected to launch its new OTC Overnight service on its OTCQX and OTCQB markets in early July,…
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
Five patients have now safely been dosed and Argenica marks another milestone in pivotal second phase trials in the battle against stroke.
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.